Sign In
Buy ACXP
$1.44
+0.0200 (+1.41%)
At Close: Jul 31, 2026
Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors
07:30am, Thursday, 17'th Apr 2025
STATEN ISLAND, N.Y. , April 17, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molec
Acurx Pharmaceuticals (ACXP) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
10:55am, Tuesday, 08'th Apr 2025
After losing some value lately, a hammer chart pattern has been formed for Acurx Pharmaceuticals (ACXP), indicating that the stock has found support. This, combined with an upward trend in earnings es
Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's What You Should Know
01:01pm, Friday, 21'st Mar 2025
Acurx Pharmaceuticals (ACXP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Acurx Pharmaceuticals, Inc. (ACXP) Q4 2024 Earnings Call Transcript
09:44am, Tuesday, 18'th Mar 2025
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q4 2024 Earnings Conference Call March 18, 2025 8:00 AM ET Company Participants Robert Shawah - Co-Founder and Chief Financial Officer David Luci - President
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
07:01am, Tuesday, 18'th Mar 2025
STATEN ISLAND, N.Y. , March 18, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibi
Acurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct Offering
04:30pm, Monday, 10'th Mar 2025
STATEN ISLAND, N.Y. , March 10, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of ant
Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering
08:00am, Friday, 07'th Mar 2025
STATEN ISLAND, N.Y. , March 7, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of anti
First ever head-to-head comparison of gut microbiome changes associated with ibezapolstat (IBZ) to other anti-CDI antibiotics in a germ-free mouse model Changes in alpha and beta microbiome diversitie
STATEN ISLAND, N.Y. , Feb. 28, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibio
Major finding provides mechanistic explanation for ibezapolstat's (IBZ) selectivity in that the predicted bactericidal interaction between IBZ and its target DNA pol IIIC is conserved across most of t
JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors
08:00am, Wednesday, 19'th Feb 2025
STATEN ISLAND, N.Y. , Feb. 19, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecu
Acurx Pharmaceuticals, Inc. Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
05:00pm, Tuesday, 07'th Jan 2025
STATEN ISLAND, N.Y. , Jan. 7, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antib
Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
05:35pm, Monday, 06'th Jan 2025
STATEN ISLAND, N.Y. , Jan. 6, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antib
Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)
08:30am, Monday, 06'th Jan 2025
Acurx has now received positive written responses from the EMA (European Medicines Agency) under its Scientific Advice Procedure that the clinical, non-clinical and CMC (Chemistry Manufacturing and Co
Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025
11:00am, Wednesday, 11'th Dec 2024
STATEN ISLAND, NY / ACCESSWIRE / December 11, 2024 / Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company") (NASDAQ:ACXP), a late-stage biopharmaceutical company developing a new class of small molecu
